Výsledky vyhledávání - "H. J Dubbink"

Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol

Autor: L. Bleeker, M. C. M. Kouwenhoven, I. de Heer, B. I. Lissenberg-Witte, A. H. Gijsbers, H. J. Dubbink, J. M. Kros, J. M. M. Gijtenbeek, E. Kurt, C. C. D. van der Rijt, A. T. Swaak-Kragten, F. Y. de Vos, H. L. van der Weide, P. J. French, M. J. van den Bent, P. Wesseling, J. E. C. Bromberg

Publikováno v: Journal of Neuro-Oncology, 162, 1, pp. 225-235
Journal of Neuro-Oncology, 162, 225-235
JOURNAL OF NEURO-ONCOLOGY, 162. SPRINGER
Journal of Neuro-Oncology, 162(1), 225-235. Kluwer Academic
Journal of Neuro-Oncology, 162(1), 225-235. Kluwer Academic Publishers
Bleeker, L, Kouwenhoven, M C M, de Heer, I, Lissenberg-Witte, B I, Gijsbers, A H, Dubbink, H J, Kros, J M, Gijtenbeek, J M M, Kurt, E, van der Rijt, C C D, Swaak-Kragten, A T, de Vos, F Y, van der Weide, H L, French, P J, van den Bent, M J, Wesseling, P & Bromberg, J E C 2023, ' Medulloblastoma in adults : evaluation of the Dutch society for neuro-oncology treatment protocol ', Journal of Neuro-Oncology, vol. 162, no. 1, pp. 225-235 . https://doi.org/10.1007/s11060-023-04285-8

Purpose Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Methods Adult medulloblastoma patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67427e41dff228838387fb83cfe695a8

Zobrazit plný text záznamu

P11.69.B IDH1/2wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared toIDH1/2wildtype glioblastomas

Autor: M P van Opijnen, C M S Tesileanu, L Dirven, P B van der Meer, M M J Wijnenga, A J P E Vincent, M L D Broekman, H J Dubbink, J M Kros, S G van Duinen, M Smits, P J French, M J van den Bent, M J B Taphoorn, J A F Koekkoek

Publikováno v: Neuro-Oncology. 24:ii74-ii74

Background IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or +7/−10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered gliob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5d55f188ae828f154324d98404dd8eb
https://doi.org/10.1093/neuonc/noac174.258

Zobrazit plný text záznamu

Prognostic value of

Autor: J A, van Ipenburg, N C, Naus, H J, Dubbink, R, van Ginderdeuren, G S, Missotten, D, Paridaens, R M, Verdijk

Publikováno v: The British journal of ophthalmology. 105(10)

To evaluate the prognostic value of clinical, histopathological and molecular features and to relate different treatment modalities to clinical outcome in conjunctival melanomas (CM).Retrospective review of clinical, histopathological andOut of 78 ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::41f1a6b78d2a8490fd960456e732182e
https://pubmed.ncbi.nlm.nih.gov/33127831

Zobrazit plný text záznamu

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Publikováno v: Neuro-Oncology. 23:1415-1415

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ffbd27c2feaee9dcadc4de2d8c3b71
https://doi.org/10.1093/neuonc/noaa115

Zobrazit plný text záznamu

CLIN-PATHOLOGY

Autor: D. Alexandru, R. Satyadev, W. So, S. H. Lee, Y. S. Lee, Y.-K. Hong, C. S. Kang, S. D. Rodgers, B. J. Marascalchi, R. G. Strom, H. Riina, U. Samadani, A. Frempong-Boadu, R. Babu, C. Sen, D. Zagzag, M. D. Anderson, T. W. Abel, P. L. Moots, Y. Odia, B. A. Orr, C. G. Eberhart, F. Rodriguez, R. T. Sweis, J. Lavingia, J. Connelly, E. Cochran, M. van den Bent, C. Hartmann, M. Preusser, T. Strobel, H. J. Dubbink, J. M. Kros, A. von Deimling, B. Boisselier, M. Sanson, K. C. Halling, K. L. Diefes, K. Aldape, C. Giannini, F. J. Rodriguez, A. H. Ligon, I. Horkayne-Szakaly, E. J. Rushing, K. L. Ligon, N. Vena, D. I. Garcia, J. Douglas Cameron, A. Raghunathan, K. Wani, T. S. Armstrong, E. Vera-Bolanos, M. Fouladi, A. Gajjar, S. Goldman, N. L. Lehman, P. Metellus, T. Mikkelsen, M. J. T. Necesito-Reyes, A. Omuro, R. J. Packer, S. Partap, I. F. Pollack, M. D. Prados, H. Ian Robbins, R. Soffietti, J. Wu, M. R. Gilbert, K. D. Aldape, M. Prosniak, L. A. Harshyne, D. W. Andrews, D. Craig Hooper, N. Kagawa, N. Hosen, N. Kijima, R. Hirayama, Y. Chiba, F. Yamamoto, M. Kinoshita, N. Hashimoto, Y. Fujimoto, T. Yoshimine, J. Hu, M. Nuno, C. Patil, J. Rudnick, S. Phuphanich, S. Bannykh, R. Chu, J. Yu, K. Black, J. Choi, D. Kim, K. W. Shim, S. H. Kim, H. Kanno, H. Nishihara, S. Tanaka, T. Yanagi, P. Buczkowicz, D.-A. Khuong-Quang, P. Rakopoulos, E. Bouffet, A. Morrison, U. Bartels, S. M. Pfister, N. Jabado, C. Hawkins, B. D. Weinberg, K. L. Newell, P. Kumar, F. Wang, S. Venneti, M. Madden, T. Coyne, J. Phillips, D. Gorovets, J. Huse, J. Kofler, C. Lu, T. Tihan, L. Sullivan, M. Santi, A. Judkins, C. Thompson, A. Perry, J. B. Iorgulescu, I. Laufer, M. Hameed, E. Lis, P. Boland, R. Komotar, M. Bilsky, A. C. Amato-Watkins, J. Neal, A. D. Rees, J. S. Davies, C. Hayhurst, C. Lu-Emerson, M. Snuderl, C. Davidson, N. D. Kirkpatrick, Y. Huang, D. G. Duda, M. Ancukiewicz, A. Stemmer-Rachamimov, T. T. Batchelor, R. K. Jain, B. Ellezam, B. J. Theeler, Z. S. Sadighi, V. Mehta, M.-D. T. Tran, A. M. Adesina, V. K. Puduvalli, J. M. Bruner

Publikováno v: Neuro-Oncology. 14:vi106-vi111

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b537326c459c7679e9153e0e97fc1a
https://doi.org/10.1093/neuonc/nos233

Zobrazit plný text záznamu

RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS

Publikováno v: Neuro-Oncology. 16:iii49-iii50

BACKGROUND: Molecular testing for MGMT promoter methylation has become of clinical importance in the diagnostic assessment of malignant gliomas since test results may guide therapeutic decision making, in particular in elderly patients with glioblast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e6d5f515a5bf3a6d31c9dae27ca367
https://doi.org/10.1093/neuonc/nou209.30

Zobrazit plný text záznamu

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

Autor: Willem Boogerd, Jacoline E C Bromberg, B. A. Zonnenberg, Pa. E. Sillevis Smitt, M. J. van den Bent, Tjeerd J. Postma, W. N. M. Dinjens, R.M. van Marion, F. H. Groenendijk, Johan M. Kros, J.M.M. Gijtenbeek, C. B. L. Zonnenberg, Walter Taal, I. van Heuvel, H. J. Dubbink

Publikováno v: Neurology, 73(21), 1792-1795. Lippincott Williams & Wilkins
Neurology, 73(21), 1792-1795. Lippincott Williams and Wilkins
Neurology, 73(21), 1792-1795. LIPPINCOTT WILLIAMS & WILKINS
Neurology, 73, 1792-5
Neurology, 73, 21, pp. 1792-5
Dubbink, H J, Taal, W, van Marion, R, Kros, J M, van Heuvel, I, Bromberg, JE, Zonnenberg, B A, Zonnenberg, C, Postma, T J, Gijtenbeek, J M M, Boogerd, W, Groenendijk, F H, Smitt, P A E S, Dinjens, W N M & van den Bent, M J 2009, ' IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide ', Neurology, vol. 73, no. 21, pp. 1792-1795 . https://doi.org/10.1212/WNL.0b013e3181c34ace

Contains fulltext : 80414.pdf (Publisher’s version ) (Closed access) BACKGROUND: Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1 or IDH2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e5ed346cea2acefc480f563a0adf63
https://pure.eur.nl/en/publications/22a5a3fe-7d04-45a0-bf24-f54af4ea2ad7

Zobrazit plný text záznamu

Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern

Autor: H J, Dubbink, R F, Hoedemaeker, T H, van der Kwast, F H, Schröder, J C, Romijn

Publikováno v: Laboratory investigation; a journal of technical methods and pathology. 79(2)

Human prostate-specific transglutaminase (hTGp) is a cross-linking enzyme, the physiologic function of which has not been established unequivocally yet. To gain insight into its distribution, we raised antisera against hTGp. By using Western blotting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4eb2527c24cb3a0bb9614436f63e0d8f
https://pubmed.ncbi.nlm.nih.gov/10068203

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání